High frequency of aspirin resistance in patients with nephrotic syndrome

Nephrology Dialysis Transplantation

Volumn 27, Issue 4, 2012, Pages 1460-1466

  Akoglu, Hadim ^a   Agbaht, Kemal ^b   Piskinpasa, Serhan ^a   Falay, Mesude Y ^a   Dede, Fatih ^a   Ozet, Gulsum ^a   Odabas, Ali Riza ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

aspirin resistance; hypercholesterolemia; nephrotic syndrome

Indexed keywords

ACETYLSALICYLIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG USE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEPHROTIC SYNDROME; PRIORITY JOURNAL; RISK FACTOR; THROMBOEMBOLISM; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; ASPIRIN; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; THROMBOSIS; YOUNG ADULT;

EID: 84858745342     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr476     Document Type: Article

References (34)

1. Singhal R, Brimble KS. Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management. Thromb Res 2006; 118: 397-407 (Pubitemid 44088559)
2. Rabelink TJ, Zwaginga JJ, Koomans HA et al. Thrombosis and hemostasis in renal disease. Kidney Int 1994; 46: 287-296 (Pubitemid 24253033)
3. Ordoñez JD, Hiatt RA, Killebrew EJ et al. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 1993; 44: 638-642 (Pubitemid 23265235)
4. Mahmoodi BK, ten Kate MK, Waanders F et al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation 2008; 117: 224-230
5. Zwaginga JJ, Koors HA, Sixma JJ et al. Thrombus formation and platelet vessel wall interaction in the nephrotic syndrome under flow conditions. J Clin Invest 1994; 931: 204-211 (Pubitemid 24030838)
6. Bennet A, Cameron JS. Platelet hyperaggregability in the nephrotic syndrome which is not dependent on arachidonic acid metabolism or on albumin concentration. Clin Nephrol 1987; 27: 182-188 (Pubitemid 17057903)
7. Machleidt C, Mettang T, Stärz E et al. Multifactorial genesis of enhanced platelet aggregability in patients with nephrotic syndrome. Kidney Int 1989; 36: 1119-1124 (Pubitemid 20049222)
8. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 2008; 51: 1829-1843 (Pubitemid 351615246)
9. Sanderson S, Emery J, Baglin T et al. Narrative review: aspirin resistance and its clinical implications. Ann Intern Med 2005; 142: 370-380 (Pubitemid 40293410)
10. Gum PA, Kottke-Marchant K, Poggio ED et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-235 (Pubitemid 32721947)
11. Pamukcu B, Oflaz H, Onur I et al. Aspirin-resistant platelet aggregation in a cohort of patients with coronary heart disease. Blood Coagul Fibrinolysis 2007; 18: 461-465 (Pubitemid 46975949)
12. Mueller MR, Salat A, Stangl P et al. Variable platelet response to lowdose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997; 78: 1003-1007 (Pubitemid 27417291)
13. Roller RE, Dorr A, Ulrich S et al. Effect of aspirin treatment in patients with peripheral arterial disease monitored with the platelet function analyzer PFA-100. Blood Coagul Fibrinolysis 2002; 13: 277-281 (Pubitemid 35001866)
14. AlbertsMJ, Bergman DL,Molner E et al. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004; 35: 175-178
15. Fateh-Moghadam S, Plöckinger U, Cabeza N et al. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 2005; 42: 99-103 (Pubitemid 40881115)
16. Ozben B, Tanrikulu AM, Ozben T et al. Aspirin resistance in hypertensive patients. J Clin Hypertens 2010; 12: 714-720
17. Charlesworth JA, Gracey DM, Pussell BA. Adult nephrotic syndrome: non-specific strategies for treatment. Nephrology (Carlton) 2008; 13: 45-50
18. Robert A, Olmer M, Sampol J et al. Clinical correlation between hypercoagulability and thrombo-embolic phenomena. Kidney Int 1987; 31: 830-835 (Pubitemid 17025917)
19. Fahal IH, McClelland P, Hay CR et al. Arterial thrombosis in the nephrotic syndrome. Postgrad Med J 1994; 70: 905-909
20. Schieppati A, Dodesini P, Benigni A et al. The metabolism of arachidonic acid by platelets in nephrotic syndrome. Kidney Int 1984; 25: 671-676 (Pubitemid 14079962)
21. Weber AA, Zimmermann KC, Meyer-Kirchrath J et al. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999; 353: 900 (Pubitemid 29126885)
22. Homoncik M, Blann AD, Hollenstein U et al. Systemic inflammation increases shear stress-induced platelet plug formation measured by the PFA-100. Br J Haematol 2000; 111: 1250-1252 (Pubitemid 32104947)
23. Modica A, Karlsson F, Mooe T. Platelet aggregation and aspirin non responsiveness increase when an acute coronary syndrome is complicated by an infection. J Thromb Haemost 2007; 5: 507-511 (Pubitemid 46680683)
24. Ziegler S, Alt E, Brunner M et al. Influence of systemic inflammation on the interpretation of response to antiplatelet therapy, monitored by PFA-100. Semin Thromb Hemost 2005; 31: 416-419 (Pubitemid 41362347)
25. Cacciapuoti F. Hyper-homocysteinemia: a novel risk factor or a powerful marker for cardiovascular diseases? Pathogenetic and therapeutical uncertainties. J Thromb Thrombolysis 2011; 32: 82-88
26. Ciaccio M, Bellia C. Hyperhomocysteinemia and cardiovascular risk: effect of vitamin supplementation in risk reduction. Curr Clin Pharmacol 2010; 5: 30-36
27. Dionisio N, Jard́n I, Salido GM et al. Homocysteine, intracellular signaling and thrombotic disorders. Curr Med Chem 2010; 17: 3109-3119
28. Leoncini G, Pascale R, Signorello MG. Effects of homocysteine on larginine transport and nitric oxide formation in human platelets. Eur J Clin Invest 2003; 33: 713-719 (Pubitemid 36918635)
29. Acikel S, Yildirir A, Aydinalp A et al. Incidence of aspirin resistance and its relationship with cardiovascular risk factors and graft function in renal transplant recipients. Transplant Proc 2008; 40: 3485-3488
30. Markuszewski L, Rosiak M, Golanski J et al. Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin? Basic Clin Pharmacol Toxicol 2006; 98: 503-509
31. Wolf A, Zalpour C, Theilmeier G et al. Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J Am Coll Cardiol 1997; 29: 479-485 (Pubitemid 27116086)
32. Gagnet C, Devynck MA, Simon A et al. Influence of hypercholesterolemia and endothelin-3 pre-treatment on the effects of shear forces on platelet aggregation and cyclic GMP content. Atherosclerosis 1999; 143: 91-97 (Pubitemid 29138706)
33. Relou IA, Hackeng CM, Akkerman JW et al. Low-density lipoprotein and its effect on human blood platelets. Cell Mol Life Sci 2003; 60: 961-971 (Pubitemid 36735124)
34. Yashiro M, Muso E, Shio H et al. Amelioration of hypercholesterolaemia by HMG-CoA reductase inhibitor (Pravastatin) improved platelet hyperaggregability in nephrotic patients. Nephrol Dial Transplant 1994; 9: 1842-